Background {#Sec1}
==========

Complete resection of hepatobiliary malignant tumors is the best method to achieve long-term survival \[[@CR1], [@CR2]\]. Major hepatectomy is often required for complete resection, and one of the main causes of unresectability is insufficient remnant liver volume (RLV). Percutaneous transhepatic portal embolization (PTPE) is a useful method for safe major hepatectomy for hepatobiliary malignant tumors \[[@CR3]\]. Although PTPE promotes hypertrophy in the non-embolized liver and increases the future remnant liver function and volume \[[@CR4]\], some patients exhibit insufficient hypertrophy at the non-embolized liver with between 2.8 and 4.5% of patients unable to undergo surgery after PTPE due to insufficient hypertrophy \[[@CR5], [@CR6]\]. Furthermore, the degree of hypertrophy and growth rate of the remnant liver after portal vein embolization (PVE) are favorable predictors of post-hepatectomy liver failure \[[@CR7]\]. Thus, increased hypertrophy after PTPE is a crucial factor.

Although it was previously reported that hepatic injury (fibrosis or cirrhosis) was an unfavorable factor for hepatic hypertrophy after PTPE \[[@CR3]\], favorable factors for hypertrophy after PTPE remain elusive. In addition, the hemodynamics of portal venous flow after PTPE has been not investigated in detail. In this study, we examined the favorable factors for remnant liver hypertrophy and hemodynamics of portal venous flow volume (pFV) after PTPE at the non-embolized lobe by ultrasound sonography (US).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between January 2004 and November 2015, 58 patients underwent PTPE for hepatectomy at the Gastroenterological Surgery I unit of Hokkaido University Hospital in Sapporo, Japan. The entire liver volume, liver resection volume, and tumor volume were calculated from contrast-enhanced computed tomography (CT) data by 3D workstations (Virtual Place Lexus; Medical Imaging Laboratory, AZE, Tokyo, Japan, and Synapse Vincent, Fujifilm Medical Co., Ltd., Tokyo, Japan). PTPE was performed in patients with an effective liver resection rate \> 60% according to the formula \[(liver resection volume -- tumor volume) / (whole liver volume -- tumor volume)\] × 100 \[[@CR8]\]. The diagnoses and surgical data of the patients are presented in Table [1](#Tab1){ref-type="table"}. We performed bile duct drainage (mainly nasobiliary drainage) before in cases which T-bil ≥ 2.0 mg/dL. PTPE were performed for the cases which T-bil \< 2.0 mg/dL.Table 1Patient diagnoses and operative proceduresnDiagnosis Hepatocellular carcinoma13 Intrahepatic cholangiocarcinoma4 Bile duct cancer34 Metastatic liver cancer2 Gallbladder cancer5Operative procedure Right hepatectomy38 Extended right hepatectomy6 Right trisegmentectomy3 Left hepatectomy1 Left trisegmentectomy4 Right hepatectomy with pancreatoduodenectomy3 Unresectable cases3

PTPE {#Sec4}
----

The PTPE method was previously reported \[[@CR9]\] and is briefly described here. Most patients underwent an ipsilateral approach, but the contralateral approach was used when the ipsilateral approach was judged to be unsuitable by interventional radiologists. After the administration of local anesthesia, the intrahepatic portal vein was punctured with an 18-gauge needle (Needle for Ultrasonically Guided Puncture; Create Medic Co., Yokohama, Japan) under US guidance. A 5.5-French sheath introducer (Introducer Set; Medikit Co., Tokyo, Japan) was inserted into the portal vein with a guidewire. Direct portography was performed to evaluate the anatomy and measurement of portal venous pressure (PVP) directly. Next, selective portography was performed with a balloon occlusion catheter (Selecon MP Catheter II; Terumo Co., Tokyo, Japan). The embolic material was absolute ethanol. The method of ethanol injection was previously reported.^9^ After repeat embolization until the resolution of hepatic parenchymal enhancement, direct portography was performed to confirm the PTPE result. Then, we directly measured PVP at the non-embolized lobe. Finally, the 5.5-French sheath was extracted by packing the puncture tract with a gelatin sponge torpedo (Spongel; Astellas Pharma Co., Tokyo, Japan).

Assessments {#Sec5}
-----------

The patients' liver volumes and RLVs were semiautomatically measured by 3D workstations using contrast-enhanced CT imaging data before PTPE and 1 and 2 weeks after PTPE. pFV was measured thrice by pulsed wave Doppler US (Toshiba SSA-700A (Aplio50), Toshiba Medical Systems Co., Ltd., Tokyo, Japan, and LOGIQ P6 BT11, GE Healthcare JAPAN Co., Ltd., Tokyo, Japan) on days 1, 3, 5, and 7 after PTPE. We calculated pFV as following, pFV = portal velocity (pulsed wave Doppler US) × πr (r = radius of portal vein)^2^. We averaged the 3 readings on each day to calculate the pFV. We measured the pFV of the umbilical portion for right-side hepatectomy, the anterior branch for left hepatectomy, and the posterior branch for left trisegmentectomy.

Patients were stratified into a considerable hypertrophy group (CH; *n* = 15) and a minimal hypertrophy group (MH; *n* = 33) based on the increase rate of RLV (IR-RLV), i.e., ≥ 40% versus \< 40%, respectively, according to the formula \[(RLV at 2 weeks after PTPE -- RLV before PTPE) / RLV before PTPE\] × 100. We investigated the favorable factors for hepatic hypertrophy and hemodynamics of pFV after PTPE. Using the formula \[(pFV after PTPE -- pFV before PTPE) / pFV before PTPE\] × 100, we evaluated the increase rate of pFV (IR-pFV) at the non-embolized lobe on days 1, 3, 5, and 7 after PTPE by US; the portal venous pressure (PVP) before and after PTPE; patients' age and sex; hemoglobin, white blood cell, C-reactive protein, aspartate aminotransferase, alanine aminotransferase, platelet, cholinesterase, albumin, total bilirubin (T-bil), and A1c glycated hemoglobin levels; hepatitis B surface antigen; hepatitis C virus antibody; the indocyanine green retention rate at 15 min (ICGR15); pathological liver fibrosis; and the receptor index \[uptake ratio of the liver to that of the liver plus heart at 15 min of technetium 99 m diethylenetriaminepentaacetic acid-galactosyl-human serum albumin scintigraphy (LHL15)\]. Patients who had portal venous recanalization after PTPE were excluded (*n* = 10, 17.2%).

We performed the assessment of hypertrophy by CT at 2 weeks because most cases (86%, 50/58) underwent hepatectomy with satisfaction for our criteria at 2 weeks after PTPE.

This study was approved by the Hokkaido University Hospital Voluntary Clinical Study Committee and was performed according to Helsinki Declaration guidelines.

Statistical analysis {#Sec6}
--------------------

Values are expressed as the mean ± standard deviation**.** Univariate analyses were performed using Student's *t*-test for continuous variables and the chi-square test for non-continuous variables. Multivariate analyses were performed using logistic regression model analyses. Pearson's correlation coefficients were used to analyze the correlation between the IR-pFV at the non-embolized lobe by US and the IR-RLV. A *P*-value of \< 0.05 was considered significant. Statistical analyses were performed using JMP Pro 12.0.1 for Windows (SAS Institute Inc., NC, USA).

Results {#Sec7}
=======

Perioperative data of patients {#Sec8}
------------------------------

Patient perioperative data are provided in Table [1](#Tab1){ref-type="table"}. The diagnoses in our study cohort were hepatocellular carcinoma (*n* = 13), intrahepatic cholangiocarcinoma (*n* = 4), bile duct cancer (*n* = 34), metastatic liver cancer (*n* = 2), and gallbladder cancer (*n* = 5). The operative procedures were right hepatectomy (*n* = 38), extended right hepatectomy (*n* = 6), right trisegmentectomy (*n* = 3), left hepatectomy (*n* = 1), left trisegmentectomy (*n* = 4), and right hepatectomy with pancreatoduodenectomy (*n* = 3). Three tumors were unresectable (*n* = 3). The mean waiting time from PTPE to surgery was 26 days (15--96). Table [2](#Tab2){ref-type="table"} reports total hepatic volume, RLV, effective liver resection rate before and after PTPE. The mean RLVs before and after PTPE were 438.6 ± 106 mL and 558.8 ± 99.9 mL, respectively (*P* \< 0.01). The median IR-RLV was 30.5%. Only one complication occurred, namely, hemobilia (1.7%). No patient exhibited transient thrombocytopenia (defined as a platelet count less than 50 × 10^3^ cells/μL). All recanalization rates after PTPE were 17.2%. However, all cases had recanalization beyond the third portal branches. No cases exhibited recanalization at second or first portal branches. Two cases of all 10 recanalization cases needed additional PVE, that is 1 case was performed PTPE, 1 case was performed TIPE. Recanalization cases showed that the mean RLVs before and after PTPE were 304.3 ± 23 mL and 397.8 ± 53.8 mL, respectively (*P* \< 0.01). The median IR-RLV was 26.9%. No cases exhibited post-hepatectomy liver failure. Regarding 8 cases could not achieve our criteria for hepatectomy at 2 weeks after PVE, 2 cases achieved our criteria for hepatectomy at 4 weeks after PVE, 3 cases at 5 weeks, 1 case at 6 weeks, 1 case at 7 weeks, and 1 case at 8 weeks.Table 2Liver volume and resection rates before and after PTPETotal liver volume (ml)Remnant liver volume (ml)Effective liver resection rate (%)Before PTPE1383.4 ± 395.5438.6 ± 10663.8 ± 7.42 weeks after PTPE1394.9 ± 459.2558.8 ± 99.954.8 ± 7.3*PTPE* percutaneous transhepatic portal embolization

Correlation between IR-RLV and high IR-pFV cases {#Sec9}
------------------------------------------------

We evaluated the IR-RLV of the cases with regard to an IR-pFV greater than 100% on days 1, 3, 5, and 7 after PTPE using ROC (receiver operating characteristics) curves to determine the cut-off values for IR-RLV. The values were 29.2% (area under the curve \[AUC\] = 0.5297, sensitivity = 59.1%, specificity = 57.7%), 37.3% (AUC = 0.6746, sensitivity = 52.4%, specificity = 74.1%), 42.4% (AUC = 0.6974, sensitivity = 47.8%, specificity = 96.0%), and 40.7% (AUC = 0.5661, sensitivity = 42.9%, specificity = 85.0%), respectively.

Clinicopathological characteristics in the CH and MH groups {#Sec10}
-----------------------------------------------------------

The patients were then classified into two groups, the CH and MH groups, based on an IR-RLV cut-off value of 40% from the above results.

The clinicopathological characteristics of the CH and MH groups are provided in Table [3](#Tab3){ref-type="table"}. The following variables were significantly different between these 2 groups: white blood cell count (4966 ± 1198/μL vs 6987 ± 2625/μL; *P* \< 0.01), T-bil (0.98 ± 0.53 mg/dL vs 1.59 ± 0.94 mg/dL; *P* = 0.02), ICGR15 (10.6 ± 3.7% vs 16.1 ± 3.9%; *P* \< 0.01), PVP after PTPE (18.2 ± 1.9 cmH~2~O vs 20.5 ± 3.7 cmH~2~O; *P* = 0.03), IR-pFV by US on day 3 after PTPE (156 ± 96% vs 89 ± 57%; *P* \< 0.01), and pathological liver fibrosis \[6.7% (1/15) vs 42.4% (14/33); *P* = 0.01\].Table 3Clinicopathological characteristics in the considerable hypertrophy and minimal hypertrophy groups by univariate analysisCharacteristicsCH (*n* = 15)MH (*n* = 33)*P*Epidemiology Age63 ± 1269 ± 70.10 Sex (male/female)11/424/90.96 HBs-Ag positive (%)1/15 (6.7%)8/33 (24%)0.14 HCV-Ab positive (%)0/15 (0%)1/33 (3%)0.49Biochemical factors WBC (/μL)4966 ± 11986987 ± 2625\< 0.01 Hb (g/dL)12.4 ± 1.513.1 ± 1.00.07 Plt (× 10^4^/μL)23.5 ± 7.924.1 ± 7.50.81 CRP (mg/dL)0.9 ± 1.30.9 ± 1.70.98 PT (%)92.1 ± 27.694.5 ± 15.10.70 Total bilirubin (mg/dL)0.98 ± 0.531.59 ± 0.940.02 AST (IU/L)53.7 ± 27.563.4 ± 57.40.53 ALT (IU/L)67.9 ± 51.484.3 ± 83.30.48 Che (IU/L)231.6 ± 53.6250.6 ± 66.90.33 Alb (g/dL)3.8 ± 0.53.9 ± 0.40.36 HbA1c (%)5.6 ± 0.95.5 ± 0.90.68 ICGR15 (%)10.6 ± 3.716.1 ± 3.9\< 0.0199mTc-GSA scintigraphy LHL150.914 ± 0.0290.915 ± 0.0740.95Portal pressure PVP (cmH~2~O) before PTPE13.2 ± 2.314.1 ± 3.30.34 PVP (cmH~2~O) after PTPE18.2 ± 1.920.5 ± 3.70.03Portal flow volume IR-pFV (%) on day 1112 ± 9090 ± 810.40 IR-pFV (%) on day 3155 ± 9690 ± 59\< 0.01 IR-pFV (%) on day 5150 ± 108111 ± 960.22 IR-pFV (%) on day 7160 ± 112109 ± 950.11Histological factors Fibrosis (f2,3,4) (%)1/15 (6.7%)14/33 (42.4%)0.01*HBs-Ag* hepatitis B surface antigen, *HCV-Ab* hepatitis C virus antibody, *WBC* white blood cell, *Hb* hemoglobin, *Plt* platelet, *CRP* C-reactive protein, *PT* prothrombin time, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *Che* cholinesterase, *Alb* albumin, *HbA1c* A1c glycated hemoglobin, *ICGR15* indocyanine green retention test at 15 min, *99mTc-GSA* technetium 99 m diethylenetriaminepentaacetic acid-galactosyl-human serum albumin, *LHL15*, receptor index: uptake ratio of the liver to that of the liver plus heart at 15 min of technetium 99 m diethylenetriaminepentaacetic acid-galactosyl-human serum albumin scintigraphy, *PVP* portal venous pressure, *PTPE* percutaneous transhepatic portal embolization, *IR-pFV* increase rate of portal venous flow volume

Multivariate analysis with logistic regression revealed that ICGR15 (odds ratio 0.5836, 95% confidence interval: 0.3432--0.9922, *P* = 0.04) and IR-pFV by US on day 3 after PTPE (odds ratio 1.0257, 95% confidence interval: 1.0018--1.0501, *P* = 0.03) were independent favorable factors of increased RLV (Table [4](#Tab4){ref-type="table"}). In addition, patients with an ICGR15 ≤ 15% and an IR-pFV on day 3 after PTPE ≥100% (favorable group, *n* = 13) exhibited significantly increased IR-RLV compared with the other patients (unfavorable group, *n* = 35) (51.6 ± 24.9% vs 23.1 ± 15.1%, *P* \< 0.01) (Fig. [1](#Fig1){ref-type="fig"}).Table 4Factors indicative of considerable hypertrophyFactorsOdds ratio95% CI*P*WBC0.99890.9977--1.00010.07Total bilirubin1.83780.3662--9.22470.45ICGR150.58360.3432--0.99220.04Fibrosis (f2,3,4)0.13050.0036--4.67040.26PVP after PTPE0.73070.4616--1.15680.18IR-pFV on day31.02571.0018--1.05010.03*WBC* white blood cell, *ICGR15* indocyanine green retention test at 15 min, *PVP* portal venous pressure, *PTPE* percutaneous transhepatic portal embolization, *IR-pFV* increase rate of portal venous flow volumeFig. 1IR-RLV according to the presence of favorable conditions, namely an IR-pFV on day 3 ≥ 100% and an ICGR15 ≤ 15%. Patients with an IR-pFV on 3 days after PTPE ≥100% and an ICGR15 ≤ 15% (favorable group) exhibited a significantly increased IR-RLV compared with other patients (unfavorable group) (*P* \< 0.01)

Table [5](#Tab5){ref-type="table"} showed multivariate analysis for factors turned out before PTPE.Table 5Factors known before PTPE indicative of considerable hypertrophyFactorsOdds ratio95% CI*P*WBC0.99940.9988--1.00010.07Total bilirubin0.75030.1657--3.39770.70ICGR150.65140.4736--0.8959\< 0.01*WBC* white blood cell, *ICGR15* indocyanine green retention test at 15 min

Correlation between the IR-pFV at the non-embolized lobe by US and IR-RLV.

In the CH group, the IR-pFV continued to increase on days 1 and 3 (113 ± 90% and 156 ± 96%, respectively). After day 3, the IR-pFV was largely maintained (151 ± 108% on day 5 and 160 ± 112% on day 7). Conversely, in the MH group, the IR-pFV generally remained unchanged after day 1 (91 ± 82% on day 1, 89 ± 57% on day 3, 112 ± 97% on day 5, and 110 ± 95% on day 7) (Fig. [2a](#Fig2){ref-type="fig"}). The correlation coefficient between the IR-pFV at the non-embolized lobe by US and the IR-RLV on day 3 was 0.7542 (Fig. [2b](#Fig2){ref-type="fig"}, Table [6](#Tab6){ref-type="table"}). The correlation coefficients on days 1, 5, and 7 were 0.4613, 0.6272, and 0.5735, respectively (Table [6](#Tab6){ref-type="table"}).Fig. 2**a** IR-pFV by US after PTPE. In the CH group, the IR-pFV continued to increase through day 1 until day 3. After day 3, the IR-pFV generally remained unchanged until day 7. The IR-pFV generally remained unchanged after day 1 in the MH group**.** \**P* \< 0.01. **b** Correlation between the IR-pFV at the non-embolized lobe by US on day 3 and the IR-RLV. The correlation coefficient was 0.7542Table 6Correlation between the IR-pFV at the non-embolized lobe by US and the IR-RLVDays after PTPECorrelation coefficientsDay 10.4613Day 30.7542Day 50.6272Day 70.5735*PTPE* percutaneous transhepatic portal embolization, *IR-pFV* increase rate of portal venous flow volume, *IR-RLV* increase rate of remnant liver volume, *US* ultrasound sonography

Discussion {#Sec11}
==========

We investigated the favorable factors for remnant liver hypertrophy and hemodynamics of portal venous flow volume after PTPE. Univariate analysis revealed that the white blood cell count, T-bil, ICGR15, PVP after PTPE, IR-pFV at the non-embolized lobe by US on day 3 after PTPE and pathological liver fibrosis were significant favorable factors for hepatic hypertrophy after PTPE. Multivariate analyses indicated that the ICGR15 and IR-pFV at the non-embolized lobe by US on day 3 after PTPE were independent favorable factors for hepatic hypertrophy after PTPE. We observed a strong positive correlation between the IR-pFV at the non-embolized lobe by US on day 3 after PTPE and the IR-RLV at 2 weeks after PTPE. In addition, we also demonstrated that the pFV after PTPE stabilized from day 3 after PTPE, even in a group of patients exhibiting increased hypertrophy. In this study, patients with an ICGR15 ≤ 15% and IR-pFV on day 3 after PTPE ≥100% were more likely to exhibit extremely favorable hepatic hypertrophy.

Rous et al. \[[@CR10]\] found that ligation of a branch of the portal vein in rabbits resulted in marked atrophy of the parenchyma of the corresponding hepatic lobe with the lobe with uninterrupted portal flow exhibiting regenerative hypertrophy. Subsequently, Makuuchi et al. \[[@CR11]\] stated that PVE increased the safety of major hepatectomy for hilar bile duct carcinoma. Kinoshita et al. \[[@CR12]\] reported the utility of preoperative PVE before hepatectomy for HCC. Currently, preoperative PVE is widely used for safely performing major hepatectomy for these hepatobiliary malignant tumors \[[@CR3]\]. PVE is classified as transileocolic portal embolization (TIPE) or PTPE according to the specific approach used. Whereas TIPE is performed via laparotomy under general anesthesia, PTPE is performed using a puncture technique with ultrasonic guidance under local anesthesia. Therefore, PTPE is more convenient and is currently more commonly used.

Some reports have demonstrated that the absolute increase in the hypertrophy of the future remnant liver ranged from 28.8 to 43% \[[@CR13], [@CR14]\]. In this study, the value was 30.5% and thus consistent with previous reports. Regarding procedure-related complications, previous reports reported rates of 12.8 to 14.9% \[[@CR15], [@CR16]\]; the rate in our study was 1.7%.

Mars et al. \[[@CR17]\] reported that urokinase-type plasminogen activator was immediately increased after partial hepatectomy. Urokinase-type plasminogen activator is induced by shear stress caused by increased blood flow \[[@CR18]\] and activates hepatocyte growth factor \[[@CR19]\]. Furthermore, nitric oxide (NO) is also induced by shear stress \[[@CR20]\]. NO is produced by cytokine-inducible NO synthase (iNOS) and endothelial NO synthase (eNOS). Regeneration was inhibited after partial hepatectomy in mice with iNOS or eNOS inhibition \[[@CR21], [@CR22]\]. Therefore, shear stress and blood flow might influence hepatic regeneration.

Recently, it was reported that the mechanisms of hepatic hypertrophy differ between post-PTPE and post-hepatectomy \[[@CR23], [@CR24]\]. Some favorable and unfavorable factors have been identified for hepatic hypertrophy after PTPE, such as age, sex, body mass index, nutrition status, previous chemotherapy, and diabetes mellitus \[[@CR14], [@CR25]\]. Chronic liver disease and cirrhosis are unfavorable factors for hypertrophy \[[@CR3]\]. In addition, the presence of major portal hypertension and portosystemic shunts are unfavorable factors for hypertrophy \[[@CR3], [@CR26]\]. Our univariate analysis also demonstrated that PVP after PTPE and pathological liver fibrosis were significant favorable factors for hepatic hypertrophy after PTPE. In general, portal pressure will increase after PVE. Chen et al. \[[@CR27]\] reported that patients with PVP below 16 cmH~2~O had a lower incidence of PHLF and patients with PVP of 20 cmH~2~O or above showed lower incidence of grade B or C PHLF. It was reported that the 90-day mortality was associated with PVP greater than 21 mmHg by Allard et al. \[[@CR28]\]. Modulation of PVP may be important for better outcome.

Mihara et al. \[[@CR29]\] reported that the ICG plasma clearance rate was a significant predictive factor for hypertrophy after PTPE. Kageyama et al. \[[@CR30]\] reported that ICGR15 \> 20% and T-bil \> 1.5 mg/dL were unfavorable factors for hypertrophy after PTPE. These previous findings are consistent with our results.

The frequency of recanalization after PTPE ranges between 7.1 and 33% \[[@CR31], [@CR32]\]. In this study, the recanalization rate was 17.2%. However, no cases exhibited recanalization at second or first portal branches. Some reports demonstrate that recanalization is a significant risk factor for poor hypertrophy \[[@CR32], [@CR33]\] possibly because pFV might be reduced at the non-embolized lobe in recanalized patients. Thus, we excluded recanalized patients.

Goto et al. \[[@CR34]\] reported that an increase in the portal blood flow velocity after PTPE on day 1 correlated with the hypertrophy rate. Our univariate and multivariate analyses revealed that the pFV on day 3 highly correlated with increased hypertrophy after PTPE. Regarding the time course, the previous study demonstrated that the increase in the portal blood flow velocity after PTPE peaked on day 1 \[[@CR34]\]. In contrast, we found that the increase in the portal blood flow after PTPE peaked on day 3 in the CH group and day 1 in the MH group. This discrepancy might be the key to good hypertrophy. Hayashi et al. \[[@CR35]\] reported that the increase in the serum bile acid levels on day 3 after PTPE was a useful predictor of favorable hypertrophy. Using a portal vein ligation model in rats, Takamura et al. \[[@CR24]\] demonstrated that the liver regeneration rate peaked between days 2 and 3 in the non-ligated lobe. Thus, we believe that the IR-pFV on day 3 after PTPE might be an important factor of hepatic hypertrophy after PTPE.

The limitation of this study is that the results may not really apply to the common population of PVE (liver metastases) because most patients were cirrhotic patients or cholestatic patients.

Conclusions {#Sec12}
===========

Preserved liver function, including ICGR15, and an increase in portal venous flow on day 3, i.e., portal venous flow shifted and added for the non-embolized lobe, are important for hepatic hypertrophy.
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